These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 36059640)

  • 1. Case report: B7-H3 CAR-T therapy partially controls tumor growth in a basal cell carcinoma patient.
    Hu G; Li G; Wen W; Ding W; Zhou Z; Zheng Y; Huang T; Ren J; Chen R; Zhu D; He R; Liang Y; Luo M
    Front Oncol; 2022; 12():956593. PubMed ID: 36059640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preconditioning of radiotherapy enhances efficacy of B7-H3-CAR-T in treating solid tumor models.
    Wang T; Zhang K; You F; Ma R; Yang N; Tian S; An G; Yang L
    Life Sci; 2023 Oct; 331():122024. PubMed ID: 37574043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel microenvironment regulated system CAR-T (MRS.CAR-T) for immunotherapeutic treatment of esophageal squamous carcinoma.
    Wang L; Wang X; Wu Y; Wang J; Zhou W; Wang J; Guo H; Zhang N; Zhang L; Hu X; Zhao Y; Miao J; Zhang Z; Chard Dunmall LS; Zhang D; Lemoine NR; Cheng Z; Wang Y
    Cancer Lett; 2023 Aug; 568():216303. PubMed ID: 37422126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CAR T cells redirected to B7-H3 for pediatric solid tumors: Current status and future perspectives.
    Epperly R; Gottschalk S; DeRenzo C
    EJC Paediatr Oncol; 2024 Jun; 3():. PubMed ID: 38957786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B7-H3-targeted CAR-T cell therapy for solid tumors.
    Li G; Wang H; Wu H; Chen J
    Int Rev Immunol; 2022; 41(6):625-637. PubMed ID: 35855615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B7-H3 specific T cells with chimeric antigen receptor and decoy PD-1 receptors eradicate established solid human tumors in mouse models.
    Huang B; Luo L; Wang J; He B; Feng R; Xian N; Zhang Q; Chen L; Huang G
    Oncoimmunology; 2020; 9(1):1684127. PubMed ID: 32002297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioactivity and safety of B7-H3-targeted chimeric antigen receptor T cells against anaplastic meningioma.
    Tang X; Liu F; Liu Z; Cao Y; Zhang Z; Wang Y; Huang J; Fan S; Zhao S; Chen Y; Li G; Wang S; Zheng M; Hu Y; Li H; Jiang C; Yang M; Yang H; Xu J; Guo G; Tong A; Zhou L
    Clin Transl Immunology; 2020; 9(6):e1137. PubMed ID: 32547742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting osteosarcoma with canine B7-H3 CAR T cells and impact of CXCR2 Co-expression on functional activity.
    Cao JW; Lake J; Impastato R; Chow L; Perez L; Chubb L; Kurihara J; Verneris MR; Dow S
    Cancer Immunol Immunother; 2024 Mar; 73(5):77. PubMed ID: 38554158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Pan-Histone Deacetylase Inhibitor Enhances the Antitumor Activity of B7-H3-Specific CAR T Cells in Solid Tumors.
    Lei X; Ou Z; Yang Z; Zhong J; Zhu Y; Tian J; Wu J; Deng H; Lin X; Peng Y; Li B; He L; Tu Z; Chen W; Li Q; Liu N; Zhang H; Wang Z; Fang Z; Yamada T; Lv X; Tian T; Pan G; Wu F; Xiao L; Zhang L; Cai T; Wang X; Tannous BA; Li J; Kontos F; Ferrone S; Fan S
    Clin Cancer Res; 2021 Jul; 27(13):3757-3771. PubMed ID: 33811153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A high-content screen of FDA approved drugs to enhance CAR T cell function: ingenol-3-angelate improves B7-H3-CAR T cell activity by upregulating B7-H3 on the target cell surface via PKCα activation.
    Lee HW; O'Reilly C; Beckett AN; Currier DG; Chen T; DeRenzo C
    J Exp Clin Cancer Res; 2024 Apr; 43(1):97. PubMed ID: 38561833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel anti-B7-H3 chimeric antigen receptor from a single-chain antibody library for immunotherapy of solid cancers.
    Birley K; Leboreiro-Babe C; Rota EM; Buschhaus M; Gavriil A; Vitali A; Alonso-Ferrero M; Hopwood L; Parienti L; Ferry G; Flutter B; Himoudi N; Chester K; Anderson J
    Mol Ther Oncolytics; 2022 Sep; 26():429-443. PubMed ID: 36159778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell-surface antigen profiling of pediatric brain tumors: B7-H3 is consistently expressed and can be targeted via local or systemic CAR T-cell delivery.
    Haydar D; Houke H; Chiang J; Yi Z; Odé Z; Caldwell K; Zhu X; Mercer KS; Stripay JL; Shaw TI; Vogel P; DeRenzo C; Baker SJ; Roussel MF; Gottschalk S; Krenciute G
    Neuro Oncol; 2021 Jun; 23(6):999-1011. PubMed ID: 33320196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B7-H3 specific CAR-T cells exhibit potent activity against prostate cancer.
    Li S; Zhang M; Wang M; Wang H; Wu H; Mao L; Zhang M; Li H; Zheng J; Ma P; Wang G
    Cell Death Discov; 2023 May; 9(1):147. PubMed ID: 37149721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B7-H3 Specific CAR T Cells for the Naturally Occurring, Spontaneous Canine Sarcoma Model.
    Zhang S; Black RG; Kohli K; Hayes BJ; Miller C; Koehne A; Schroeder BA; Abrams K; Schulte BC; Alexiev BA; Heimberger AB; Zhang A; Jing W; Ng JCK; Shinglot H; Seguin B; Salter AI; Riddell SR; Jensen MC; Gottschalk S; Moore PF; Torok-Storb B; Pollack SM
    Mol Cancer Ther; 2022 Jun; 21(6):999-1009. PubMed ID: 35405743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B7-H3-Targeted CAR-T Cells Exhibit Potent Antitumor Effects on Hematologic and Solid Tumors.
    Zhang Z; Jiang C; Liu Z; Yang M; Tang X; Wang Y; Zheng M; Huang J; Zhong K; Zhao S; Tang M; Zhou T; Yang H; Guo G; Zhou L; Xu J; Tong A
    Mol Ther Oncolytics; 2020 Jun; 17():180-189. PubMed ID: 32346608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. STRIvE-02: A First-in-Human Phase I Study of Systemically Administered B7-H3 Chimeric Antigen Receptor T Cells for Patients With Relapsed/Refractory Solid Tumors.
    Pinto N; Albert CM; Taylor MR; Ullom HB; Wilson AL; Huang W; Wendler J; Pattabhi S; Seidel K; Brown C; Gustafson JA; Rawlings-Rhea SD; Cheeney SHE; Burleigh K; Gustafson HH; Orentas RJ; Vitanza NA; Gardner RA; Jensen MC; Park JR
    J Clin Oncol; 2024 Dec; 42(35):4163-4172. PubMed ID: 39255444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical Evaluation of B7-H3-specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia.
    Lichtman EI; Du H; Shou P; Song F; Suzuki K; Ahn S; Li G; Ferrone S; Su L; Savoldo B; Dotti G
    Clin Cancer Res; 2021 Jun; 27(11):3141-3153. PubMed ID: 33531429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switchable CAR T cell strategy against osteosarcoma.
    Hidalgo L; Somovilla-Crespo B; Garcia-Rodriguez P; Morales-Molina A; Rodriguez-Milla MA; Garcia-Castro J
    Cancer Immunol Immunother; 2023 Aug; 72(8):2623-2633. PubMed ID: 37062034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells.
    Du H; Hirabayashi K; Ahn S; Kren NP; Montgomery SA; Wang X; Tiruthani K; Mirlekar B; Michaud D; Greene K; Herrera SG; Xu Y; Sun C; Chen Y; Ma X; Ferrone CR; Pylayeva-Gupta Y; Yeh JJ; Liu R; Savoldo B; Ferrone S; Dotti G
    Cancer Cell; 2019 Feb; 35(2):221-237.e8. PubMed ID: 30753824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intraventricular B7-H3 CAR T Cells for Diffuse Intrinsic Pontine Glioma: Preliminary First-in-Human Bioactivity and Safety.
    Vitanza NA; Wilson AL; Huang W; Seidel K; Brown C; Gustafson JA; Yokoyama JK; Johnson AJ; Baxter BA; Koning RW; Reid AN; Meechan M; Biery MC; Myers C; Rawlings-Rhea SD; Albert CM; Browd SR; Hauptman JS; Lee A; Ojemann JG; Berens ME; Dun MD; Foster JB; Crotty EE; Leary SES; Cole BL; Perez FA; Wright JN; Orentas RJ; Chour T; Newell EW; Whiteaker JR; Zhao L; Paulovich AG; Pinto N; Gust J; Gardner RA; Jensen MC; Park JR
    Cancer Discov; 2023 Jan; 13(1):114-131. PubMed ID: 36259971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.